** Johnson & Johnson JNJ.N halved its expectations for costs this year related to new tariffs and raised full-year sales and profit forecast on Wednesday after a strong quarter for its flagship cancer drug Darzalex and cardiovascular devices
INNOVATIVE MEDICINES SEGMENT TO LEAD GAINS
** J.P.Morgan ("neutral," PT: $185) says JNJ's underlying business is well positioned and capable of generating over 5% revenue growth with the innovative medicines segment and medtech portfolio supporting growth
** Morningstar (fair value: $172) says on potential pharmaceutical tariffs, JNJ is in a good position with most US-bound products already made in the U.S.
** TD Cowen ("buy," PT: $185) notes JNJ has numerous milestones ahead in the innovation medicine pipeline including TAR-200 for bladder cancer that is set to be commercialized later this year
** Leerink Partners ("market perform," PT: $171) says TAR-200 is well positioned to gain significant market share, aiding co's growth prospects
(Reporting by Kanchana Chakravarty in Bengaluru)
((Kanchana.Chakravarty@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。